Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT05080179
Other study ID # 844564
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date December 11, 2020
Est. completion date January 28, 2021

Study information

Verified date October 2022
Source University of Pennsylvania
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Eligible participants who were active beneficiaries of a large insurer living in Pennsylvania were sent an email encouraging them to download the contact tracing app in Pennsylvania, COVID Alert PA. Participants will be randomly assigned to one of four conditions in a 2 (Self-benefit vs. Other-Benefit) x 2 (Social Norms Present vs. Social Norms absent) design. All participants received an email that said : "COVID Alert PA is the official Exposure Notification App from the Pennsylvania Department of Health. Join Penn Medicine in the fight against COVID-19 and download COVID Alert PA today!" ---Investigators manipulated the content here--- "The app uses Bluetooth to sense when one person is in close contact with another person with the app. If someone tests positive for COVID-19, and they decide to upload the information to the health department, people who have the app and who have been in contact with them will be alerted. If you are interested in downloading the app, please click COVID Alert PA. We appreciate you joining our efforts. Together we can beat COVID-19!" In the Other-Benefit condition, it said: "It can help you reduce your risk of unknowingly spreading the virus to your friends, family, and larger community." In the Self-Benefit condition, it said: "It can help you determine where and when to get testing, and how to get care if you need it." In the Social Norms Present condition, it said: "Over 650,000 Pennsylvanians have already downloaded the app!" In the Social Norms Absent condition, it said the statement about social norms above. Participants who do not open the initial email received a follow-up email.


Recruitment information / eligibility

Status Completed
Enrollment 16903
Est. completion date January 28, 2021
Est. primary completion date January 28, 2021
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group N/A and older
Eligibility Inclusion Criteria: - Eligible participants were active beneficiaries of a large insurer living in Pennsylvania. Exclusion Criteria: - Participants who did not subscribe to offers and promotions emails were excluded, as were Medigap beneficiaries.

Study Design


Related Conditions & MeSH terms


Intervention

Behavioral:
Self-Benefit/Social Norm
As part of their email, they will read, "It can help you determine where and when to get testing, and how to get care if you need it." and "Over 650,000 Pennsylvanians have already downloaded the app!"
Self-Benefit/No Social Norm
As part of their email, they will read, "It can help you determine where and when to get testing, and how to get care if you need it." They will not read any information about the number of Pennsylvanians who downloaded the app.
Other Benefit/Social Norm
As part of their email, they will read, "It can help you reduce your risk of unknowingly spreading the virus to your friends, family, and larger community." and "Over 650,000 Pennsylvanians have already downloaded the app!"
Other Benefit/No Social Norm
As part of their email, they will read, "It can help you reduce your risk of unknowingly spreading the virus to your friends, family, and larger community." They will not read any information about the number of Pennsylvanians who downloaded the app.

Locations

Country Name City State
United States Independence Blue Cross (IBX) Philadelphia Pennsylvania

Sponsors (2)

Lead Sponsor Collaborator
University of Pennsylvania Pennsylvania Department of Health

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Click on Link to Download COVID Alert PA App The investigators measured choice to click on the link to download the COVID Alert PA app or not, conditional on opening the email. Because participants may not immediately open their e-mail, or may return to the e-mail to click the link, we allowed for a period of approximately 7 weeks or 48 days from date of initial e-mail for completion of outcome measure. 48 days
See also
  Status Clinical Trial Phase
Recruiting NCT06065033 - Exercise Interventions in Post-acute Sequelae of Covid-19 N/A
Completed NCT06267534 - Mindfulness-based Mobile Applications Program N/A
Completed NCT05047601 - A Study of a Potential Oral Treatment to Prevent COVID-19 in Adults Who Are Exposed to Household Member(s) With a Confirmed Symptomatic COVID-19 Infection Phase 2/Phase 3
Recruiting NCT04481633 - Efficacy of Pre-exposure Treatment With Hydroxy-Chloroquine on the Risk and Severity of COVID-19 Infection N/A
Recruiting NCT05323760 - Functional Capacity in Patients Post Mild COVID-19 N/A
Completed NCT04612972 - Efficacy, Safety and Immunogenicity of Inactivated SARS-CoV-2 Vaccines (Vero Cell) to Prevent COVID-19 in Healthy Adult Population In Peru Healthy Adult Population In Peru Phase 3
Completed NCT04537949 - A Trial Investigating the Safety and Effects of One BNT162 Vaccine Against COVID-19 in Healthy Adults Phase 1/Phase 2
Recruiting NCT05494424 - Cognitive Rehabilitation in Post-COVID-19 Condition N/A
Active, not recruiting NCT06039449 - A Study to Investigate the Prevention of COVID-19 withVYD222 in Adults With Immune Compromise and in Participants Aged 12 Years or Older Who Are at Risk of Exposure to SARS-CoV-2 Phase 3
Enrolling by invitation NCT05589376 - You and Me Healthy
Completed NCT05158816 - Extracorporal Membrane Oxygenation for Critically Ill Patients With COVID-19
Recruiting NCT04341506 - Non-contact ECG Sensor System for COVID19
Completed NCT04384445 - Zofin (Organicell Flow) for Patients With COVID-19 Phase 1/Phase 2
Completed NCT04512079 - FREEDOM COVID-19 Anticoagulation Strategy Phase 4
Active, not recruiting NCT05975060 - A Study to Evaluate the Safety and Immunogenicity of an (Omicron Subvariant) COVID-19 Vaccine Booster Dose in Previously Vaccinated Participants and Unvaccinated Participants. Phase 2/Phase 3
Active, not recruiting NCT05542862 - Booster Study of SpikoGen COVID-19 Vaccine Phase 3
Terminated NCT05487040 - A Study to Measure the Amount of Study Medicine in Blood in Adult Participants With COVID-19 and Severe Kidney Disease Phase 1
Withdrawn NCT05621967 - Phonation Therapy to Improve Symptoms and Lung Physiology in Patients Referred for Pulmonary Rehabilitation N/A
Terminated NCT04498273 - COVID-19 Positive Outpatient Thrombosis Prevention in Adults Aged 40-80 Phase 3
Active, not recruiting NCT06033560 - The Effect of Non-invasive Respiratory Support on Outcome and Its Risks in Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-COV-2)-Related Hypoxemic Respiratory Failure